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Hesperidin and capsaicin, but not 
the combination, prevent hepatic 
steatosis and other metabolic 
syndrome-related alterations in 
western diet-fed rats
Andrea Mosqueda-Solís1,3, Juana Sánchez1,2,4, Bárbara Reynés1,2,4, Mariona Palou1,4, 
María P. Portillo3,4, Andreu Palou1,2,4 & Catalina Picó1,2,4
We aimed to assess the potential effects of hesperidin and capsaicin, independently and in combination, 
to prevent the development of obesity and its related metabolic alterations in rats fed an obesogenic 
diet. Three-month-old male Wistar rats were divided into 5 groups: Control (animals fed a standard 
diet), WD (animals fed a high fat/sucrose (western) diet), HESP (animals fed a western diet + hesperidin 
(100 mg/kg/day)), CAP (animals fed a western diet + capsaicin (4 mg/kg/day)), and HESP + CAP (animals 
fed a western diet + hesperidin (100 mg/kg/day) + capsaicin (4 mg/kg/day)). Hesperidin and capsaicin 
were administered by gavage. Capsaicin decreased body fat gain and prevented insulin resistance, 
whereas hesperidin showed little effect on body fat gain and no apparent effects on insulin resistance. 
No additive effects were observed with the combination. Capsaicin and hesperidin, separately, 
improved blood lipid profile, diminished hepatic lipid accumulation, and prevented non-alcoholic 
steatohepatitis in western diet-fed rats, but the combination showed lower effects. Hesperidin 
alone, and to a lesser extent capsaicin or the combination, displayed hypotensive effects in western 
diet-fed rats. In conclusion, capsaicin and hesperidin, separately, exhibit health beneficial effects on 
metabolic syndrome-related alterations in western diet-fed rats, but the effects are mitigated with the 
combination.
Obesity has reached epidemic proportions globally. In 2016, more than 1.9 billion adults worldwide were over-
weight, and of these over 600 million were clinically obese1. Obesity is the consequence of a prolonged disruption 
in energy homeostasis, in which the energy gain exceeds the energy expenditure. This condition is considered as a 
multifactorial disease that is influenced by lifestyle, cultural, environmental, genetic, physiological and metabolic 
factors. Notably, the intake of western diets, characterized especially in high consume of simple carbohydrates 
and saturated fats, are leading to an increase in the prevalence of obesity and its related alterations, such as insulin 
resistance, hyperlipemia and non-alcoholic fatty liver, among others2. Attention of the scientific community is 
focused on the implementation of innovative and effective strategies for the prevention and treatment for this 
pathology and its comorbidities3.
Nowadays the use of natural bioactive compounds is trending as alternative methods for the treatment and 
management of obesity and related diseases, but the efficacy of such approaches depends on the absorption, 
metabolism and bioavailability of such compounds, which may be influenced by disease state4. In addition, pos-
sible interactions between bioactive agents, leading to additive or synergistic effects or, on the contrary, to a 
decrease in their efficacy, should be considered. These aspects may have important implications for functional 
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food development and assessment. However, no much information is available regarding this issue. The study is 
of interest since the level of a single natural compound may be too low to exert sufficient beneficial effects. By con-
trast, the combination of compounds acting via an additive and/or synergistic mode to either the same or diverse 
targets may be of interest in preventing a pathological process.
For hesperidin (C28H34O15), a flavanone present in citrus fruit, diverse biological activities of therapeutic 
interest have been described, including the capacity to lower serum and liver triacylglycerols (TG) as well as 
anti-adipogenic, anti-inflammatory, antioxidant and insulin-sensitizing properties5–8. Therefore, hesperidin may 
be of interest to improve obesity-related disorders. In fact, several studies, including preclinical and clinical trials, 
have demonstrated that hesperidin may have therapeutic effects on a great variety of diseases, such as cardiovas-
cular diseases, diabetes, cancer, and neurological and psychiatric disorders, among others9.
Other compounds of potential interest are the capsaicinoids (also known as capsinoids), a group of molecules 
naturally present in chilli peppers. The most abundant and studied is the capsaicin (trans-8-methyl-N-vanillyl-
6-nonenamide (C18H27NO3), which is responsible for the pungent sensation10,11. Capsaicin is recognized for its 
potential anti-inflammatory, antioxidant, antimicrobial, anticancer, and antiobesity properties among others12. 
Several studies have demonstrated that capsaicin decreases body weight gain, hepatic lipid accumulation and 
insulin resistance induced by high-fat diet feeding13,14. The anti-obesity effects of capsaicin have been related in 
part to its capacity to stimulate the sympathetic nervous system and thus to reduce energy intake and increase 
energy expenditure and fat oxidation, through the effects of catecholamines12. However, it is not clear whether 
the long-term effects of capsaicin on obesity may be explained by this mechanism. It is accepted that much of the 
effects of capsaicin on metabolic health, particularly linked to its fat-lowering action, are caused by stimulation 
of the transient receptor potential cation channel subfamily V member 1 (TRPV1)15,16. TRPV1, also known as 
capsaicin receptor, belongs to the family of non-selective cation channels with high calcium permeability17. This 
is highly expressed in sensory neurons and in vasculature, adipose, and liver tissues18,19. TRPV1 activation has 
been described to result in recruitment of catecholaminergic neurons in the rostral ventrolateral medulla of the 
brain20. Capsaicin-induced calcium influx through TRPV1 channels has been shown to prevent adipogenesis and 
obesity in wild-type mice under high-fat diet feeding but not in TRPV1 knockout mice, indicating that TRPV1 is 
directly involved in these effects in vivo16.
Considering that hesperidin and capsaicin can affect lipid metabolism and induce triacylglycerol 
(TG)-lowering effects by different mechanisms, the combined effects of both compounds on obesity and related 
metabolic alterations is of interest. In this context, the aim of this study was to screen the potential effects of die-
tary hesperidin and capsaicin, separately, and the combination of both compounds (hesperidin + capsaicin) to 
prevent the development of obesity and its related metabolic alterations, particularly insulin resistance, dyslipi-
demia, fatty liver disease and hypertension, induced in rats by feeding a western diet.
Results
Body weight, food intake and circulating parameters. Results on body weight and body fat, liver 
weight, and food intake of the 5 groups of animals are summarized in Table 1.
At the age of 5 months, after 8 weeks of treatment, no significant differences in body weight were found among 
the 5 experimental groups. However, the western diet (WD) group, but not the capsaicin (CAP) group, showed 
higher body weight gain than controls. Animals of the hesperidin (HESP) and HESP + CAP groups showed 
intermediate values (P < 0.05, LSD post-hoc analysis). Capsaicin-treated animals also displayed, at the end of 
the intervention period, lower body fat percentage than animals of the WD group, but higher than the control 
group. Body fat content in HESP and the HESP + CAP groups was slightly higher than that of the CAP group, 
and not significantly different from the WD group (P < 0.05, LSD post-hoc analysis). Animals in the WD group, 
but not animals in the CAP group, also showed higher liver weight than the controls, whereas animals treated 
with hesperidin or with the combination of both compounds showed intermediate values (P < 0.05, LSD post-hoc 
analysis). Regarding food intake, animals of the WD group showed greater cumulative energy intake than the 
controls, whereas WD-fed animals treated with hesperidin, capsaicin or the combination of both compounds 
showed intermediate values (P < 0.05, LSD post-hoc analysis).
Circulating levels of glucose, insulin, leptin, TG and non-esterified fatty acids (NEFA) under ad libitum and 
fasting conditions are showed in Table 2. Non-significant differences were found among groups in glucose and 
insulin levels in both conditions. However, the HOMA-IR was different among groups. Capsaicin-treated animals 
Control WD HESP CAP HESP + CAP
Initial body weight (g) 362 ± 16 353 ± 8 351 ± 15 356 ± 11 358 ± 15
Final body weight (g) 428 ± 19 443 ± 14 433 ± 14 423 ± 15 433 ± 19
Body weight gain (3–5 months) (g) 66 ± 7a 91 ± 9b 83 ± 4a,b 67 ± 4a 75 ± 8a,b
Initial body fat (%) 10.8 ± 0.7 10.8 ± 0.8 10.7 ± 0.7 10.9 ± 0.4 10.9 ± 0.8
Final body fat (%) 11.5 ± 0.5a 18.4 ± 1.5b 15.9 ± 0.5b,c 15.1 ± 0.4c 15.9 ± 1.0b,c
Liver (g) 12.5 ± 0.7a 14.6 ± 0.3b 13.9 ± 0.5a,b 13.0 ± 0.4a,c 14.1 ± 0.5b,c
Cumulative food intake (3–5 months) (Kcal) 3970 ± 151a 4683 ± 356b 4431 ± 104a,b 4337 ± 191a,b 4351 ± 242a,b
Table 1. Weight-related parameters and food intake. Initial and final body weight and body fat (before and 
at the end of treatment, respectively) are indicated. Data are mean ± SEM. One-way ANOVA was used to 
determine differences between groups followed by a least significance difference (LSD) post hoc analysis 
(P < 0.05), a ≠ b ≠ c.
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showed lower values with respect to the animals from the WD and HESP groups (P < 0.05, LSD post-hoc analy-
sis). Animals of the control and HESP + CAP groups showed intermediate levels. Glucose and insulin levels were 
lower under fasting conditions with respect to levels in the fed state in all groups except in the HESP + CAP group 
(for both glucose and insulin) and in the HESP group (for insulin) (P < 0.05, Paired t test). Animals on the WD 
group showed greater plasma leptin levels (both under fed and fasting conditions) than control animals (P < 0.05, 
LSD post-hoc analysis). Notably, animals of the CAP and HESP + CAP groups showed lower fed-state leptin levels 
than animals on the WD group and intermediate levels between control and WD animals under fasting condi-
tions. All groups showed lower leptin levels under fasting conditions compared to levels under feeding conditions 
(P < 0.05, Paired t test). Animals on the WD group showed higher circulating TG levels under feeding conditions 
than the control animals (P < 0.05, LSD post-hoc analysis). TG levels were partially normalised to control levels in 
the HESP and CAP groups, but not in the HESP + CAP group (P < 0.05, LSD post-hoc analysis). No significant 
differences were found among groups regarding TG levels under fasting conditions. However, fasting TG levels 
were significantly lower than fed-state TG levels in the WD and HESP + CAP groups.
Regarding NEFA, animals on the WD group showed higher circulating levels under feeding conditions than 
the control animals (P < 0.05, LSD post-hoc analysis). HESP, CAP and HESP + CAP groups showed lower levels 
than animals on the WD group, but higher than controls (P < 0.05, LSD post-hoc analysis). No significant differ-
ences were found among groups regarding NEFA levels under fasting conditions. NEFA levels increased under 
fasting conditions in the control and HESP groups (P < 0.05, paired t test). No significant differences between 
groups were found regarding the markers of liver damage aspartate transaminase (AST) and alanine transaminase 
(ALT).
Energy expenditure, locomotive activity and respiratory exchange ratio. No differences were 
found concerning energy expenditure at the age of 5 months (data not shown). Animals fed a western diet 
showed a trend to lower locomotive activity compared to controls, but differences were not significant (Fig. 1a). 
Respiratory exchange ratio (RER) was decreased in all western diet-fed groups with respect to controls (P < 0.05, 
LSD post-hoc analysis), but no differences were found among them (Fig. 1a).
Blood pressure. Animals fed a western diet and treated with hesperidin showed lower systolic and dias-
tolic blood pressure than western diet-fed animals and even the control animals (P < 0.05, LSD post-hoc analy-
sis) (Fig. 1b). Values of diastolic blood pressure in the control group were somewhat higher than those usually 
described in Wistar rats21, but within the same range as those described by other authors22. The treatment with 
capsaicin or the combination of hesperidin and capsaicin was also associated with decreased values of diastolic 
blood pressure, and a trend to lower systolic blood pressure, reaching values not significantly different from 
controls.
Control WD HESP CAP HESP + CAP
Glucose (mg/dL)
  Ad libitum 127 ± 4 123 ± 3 119 ± 4 119 ± 2 120 ± 5
  14 h fasting 100 ± 5* 104 ± 8* 100 ± 3* 97 ± 4* 107 ± 5
Insulin (μg/L)
  Ad libitum 1.29 ± 0.25 1.60 ± 0.24 1.56 ± 0.10 1.22 ± 0.09 1.71 ± 0.36
  14 h fasting 0.83 ± 0.24* 1.07 ± 0.18* 1.10 ± 0.20 0.72 ± 0.14* 0.75 ± 0.11
HOMA-IR
  14 h fasting 3.69 ± 0.80a,b 7.07 ± 1.38a 6.77 ± 1.31a 3.60 ± 0.68b 4.93 ± 0.71a,b
Leptin (μg/L)
  Ad libitum 5.30 ± 0.45a 12.19 ± 1.65b 9.71 ± 1.04b,c 8.08 ± 0.59c 8.20 ± 0.99c
  14 h fasting 2.08 ± 0.28a,* 5.11 ± 0.97b,* 4.35 ± 0.82b,* 3.37 ± 0.51a,b,* 3.50 ± 0.72a,b,*
TG (mg/mL)
  Ad libitum 0.730 ± 0.127a 1.82 ± 0.25b 1.39 ± 0.22a,b 1.39 ± 0.18a,b 1.8 ± 0.32b
  14 h fasting 0.769 ± 0.124 0.717 ± 0.049* 0.905 ± 0.141 0.816 ± 0.171 0.928 ± 0.196*
NEFA (mmol/L)
  Ad libitum 0.498 ± 0.036a 0.984 ± 0.084b 0.781 ± 0.046c 0.740 ± 0.046c 0.765 ± 0.063c
  14 h fasting 1.19 ± 0.11* 0.902 ± 0.058 1.11 ± 0.14* 0.978 ± 0.089 0.938 ± 0.194
AST (U/L)
  Ad libitum 53.0 ± 5.0 54.8 ± 3.1 54.1 ± 4.6 52.3 ± 8.3 44.2 ± 3.0
ALT (U/L)
  Ad libitum 9.14 ± 1.49 8.25 ± 2.33 11.8 ± 1.6 8.25 ± 1.73 8.00 ± 2.63
Table 2. Blood parameters of control (C), western diet (WD), hesperidin (HESP), capsaicin (CAP), and 
hesperidin and capsaicin (HESP + CAP) rats at the end of treatment. Data are mean ± SEM. One-way ANOVA 
was used to determine differences between groups under ad libitum and fasting condition separately, followed 
by a least significance difference (LSD) post-hoc analysis (P < 0.05), a ≠ b ≠ c. *P < 0.05 fasting versus ad libitum 
condition (Paired t-test). HOMA-IR: homeostatic model assessment for insulin resistance; TG: triacylglycerol; 
NEFA: non-esterified fatty acids; AST: aspartate transaminase (AST); ALT: alanine transaminase.
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Hepatic lipid content and histological analysis. Figure 2a shows the hepatic lipid content of animals 
after the intervention period. Animals of the WD group displayed a significant increase (112%) in the lipid con-
tent with respect to controls. Notably, western diet-fed animals treated with either hesperidin or capsaicin sepa-
rately and, to a lesser extent with the combination, showed significantly lower hepatic lipid content with respect 
to the WD group (39%, 38%, and 15% decrease, respectively). Nevertheless, all western diet-fed groups displayed 
higher hepatic lipid content than controls (P < 0.05, LSD post-hoc analysis). Liver histological analysis (Fig. 2b–f) 
revealed no signs of steatosis in the control animals. However, western diet-fed groups presented different degrees 
of hepatic steatosis: grade 1 (HESP and CAP groups), grade 2 (HESP + CAP group), and grade 3 (WD group). 
Moreover, the WD and HESP + CAP groups exhibited the presence of hepatocyte ballooning, necrotic hepato-
cytes and infiltrated lymphocytes, which are indicative characteristics of non-alcoholic steatohepatitis (NASH), 
and distinguished from simple steatosis23. These results suggest that hesperidin and capsaicin separately, but not 
the combination, can prevent the development of NASH induced by western diet feeding.
mRNA and protein expression of energy metabolism-related genes in liver. mRNA and protein 
expression levels of selected genes related to energy metabolism in liver in the different groups of animals are 
summarized in Fig. 3.
WD group presented higher expression levels of the lipogenesis-related genes Srebf1, and Scd1 with respect 
to controls (P < 0.05, LSD post-hoc analysis). The increase was prevented in hesperidin-treated animals and, in 
the case of Srebf1, in animals treated with the combination of both molecules. Animals treated with capsaicin or 
the combination showed a trend to lower Scd1 mRNA expression levels than western diet-fed animals, but not 
different from the controls (P < 0.05, LSD post-hoc analysis).
Animals treated with hesperidin, capsaicin or the combination also showed lower expression levels of Fasn 
with respect to animals of the WD group (P < 0.05, LSD post-hoc analysis), whereas the control animals showed 
intermediate levels. Animals treated with the combination displayed greater expression levels of Gadph than the 
controls and heperidin-treated animals, whereas the WD and CAP groups exhibited intermediate levels (P < 0.05, 
LSD post-hoc analysis).
Regarding fatty acid oxidation-related genes, the WD group showed increased expression levels of Ppara and 
Cpt1a, whereas animals of the HESP and CAP groups showed decreased (or a trend to decreased) expression 
levels, reaching values not different from controls. However, this trend was not observed in animals treated with 
Figure 1. (a) Locomotive activity and respiratory exchange ratio (RER) after 6 weeks of treatment, and (b) systolic 
and diastolic blood pressure after 5 weeks of treatment, of control (C), western diet (WD), hesperidin (HESP), 
capsaicin (CAP), and hesperidin and capsaicin (HESP + CAP) groups. Data are mean ± SEM (n = 7–8). Statistical 
analysis between groups was performed by one-way ANOVA, followed by LSD post-hoc analysis (P < 0.05), 
a ≠ b ≠ c.
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the combination, which exhibited expression levels similar to the WD group. A similar pattern was observed for 
mRNA expression levels of Fgf21, but differences among groups were not significant. Changes between groups 
regarding specific CPT1 protein levels were similar to those observed for transcript levels. Animals treated with 
the combination displayed higher CPT1 levels than animals of the control, HESP and CAP groups (P < 0.05, LSD 
post-hoc analysis).
The expression level of the glucose metabolism related gene Pklr, was significantly increased in the WD group 
with respect to controls (P < 0.05, LSD post-hoc analysis). Notably, hesperidin and capsaicin, individually or the 
combination of both, normalised their expression to the control levels. No significant differences were found 
regarding Gck expression levels among groups.
Regarding insulin and leptin signalling, the HESP, CAP and HESP + CAP groups showed lower expression 
levels of Insr than control and WD groups, with no significant differences among them (P < 0.05, LSD post-hoc 
analysis); however, no significant changes were observed in Irs1 expression among groups. In turn, the HESP 
group showed decreased Lepr mRNA expression levels than the WD and the HESP + CAP groups, while the con-
trols and animals treated with capsaicin showed intermediate levels (P < 0.05, LSD post-hoc analysis).
The gene and protein expression levels of capsaicin receptor Trpv1 and of Ucp2 were also studied to ascertain 
potential mechanisms involved in the hepatic health benefits shown by capsaicin treatment alone, but not by the 
combination of hesperidin and capsaicin (Fig. 4). Animals treated with capsaicin showed greater Trpv1 mRNA 
Figure 2. (a) Hepatic lipid content, and (b–f) representative liver slides stained with hematoxylin/eosin (x20) 
and numerical grading of hepatic steatosis in liver of control (C), western diet (WD), hesperidin (HESP), 
capsaicin (CAP), and hesperidin and capsaicin (HESP + CAP) groups at the end of treatment. In a), data are 
mean ± SEM (n = 7–8). Statistical analysis between groups was performed by one-way ANOVA, followed by 
LSD post-hoc analysis (P < 0.05), a ≠ b ≠ c ≠ d. Symbol in images: PT: portal triad, b: ballooned hepatocytes, 
arrow: necrotic hepatocyte, arrowhead: lymphocytes.
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level than the controls and animals treated with hesperidin. However, animals treated with the combination 
displayed intermediate levels, similar to those of the WD group. No significant differences between groups were 
found concerning protein levels of TRPV1. Regarding Ucp2, animals treated with capsaicin displayed higher 
mRNA levels and higher UCP2 protein levels than the control, HESP and HESP + CAP groups (P < 0.05, LSD 
post-hoc analysis).
Expression of energy metabolism-related genes in rWAT. The mRNA levels of selected genes related 
to energy metabolism in the rWAT in the different groups of animals are showed in Fig. 5. The retroperitoneal 
depot was chosen as a representative of WAT because of its high metabolic activity compared to other depots24 
and its relationship with the development of insulin resistance and type 2 diabetes25.
Animals treated with capsaicin or the combination of hesperidin and capsaicin displayed lower expression 
levels of the lipogenesis-related genes Pparg and Srebf1 with respect to the WD group (P < 0.05, LSD post-hoc 
analysis). Animals treated with hesperidin also showed lower expression levels of Pparg with respect to the WD 
group, but the decrease was less marked than that occurring in the CAP and HESP + CAP groups (P < 0.05, LSD 
post-hoc analysis). No significant differences were found between the controls and the WD group concerning the 
expression levels of Pparg and Srebf1. Fasn and Gpat expression levels were decreased in all groups of animals 
Figure 3. Expression of genes related to energy metabolism (lipogenesis, fatty acid oxidation, glucose uptake 
and metabolism, and insulin and leptin signaling) and CPT1 protein levels in liver of control (C), western 
diet (WD), hesperidin (HESP), capsaicin (CAP), and hesperidin and capsaicin (HESP + CAP) rats at the end 
of treatment. mRNA levels were measured by real-time PCR. Specific CPT1 levels were measured by western 
blot. Representative bands for CPT1 and β-actin (deriving from the same gel) are shown. mRNA and protein 
levels were expressed as a percentage of the control group. Data are mean ± SEM (n = 7–8). Statistical analysis 
between groups was performed by one-way ANOVA, followed by LSD post-hoc analysis (P < 0.05), a ≠ b ≠ c.
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under western diet feeding with respect to controls (P < 0.05, LSD post-hoc analysis), with no significance differ-
ences among them.
Regarding fatty acid uptake-related genes, HESP, CAP and HESP + CAP displayed lower expression levels of 
Lpl than the control and WD groups. The decrease in the CAP and HESP + CAP groups was more marked and 
significant than that occurring for the HESP group (P < 0.05, LSD post-hoc analysis). However, no significant 
differences between groups were found regarding LPL protein levels. The CAP and HESP + CAP groups also dis-
played a decrease in Cd36 mRNA levels with respect to the WD group (P < 0.05, LSD post-hoc analysis) whereas 
no changes were observed in the HESP group. No significant differences were found between the controls and the 
WD group concerning the expression levels of both genes.
The CAP and HESP + CAP groups displayed lower expression levels of the lipolysis related genes Pnpla2 and 
Lipe with respect to the control, WD and HESP groups (P < 0.05, LSD post-hoc analysis). The HESP group also 
showed lower mRNA levels of Pnpla2 than the WD group, but the decrease was less marked than that occurring 
in the CAP and HESP + CAP groups (P < 0.05, LSD post-hoc analysis). No significant differences were found 
between the control and the WD groups concerning the expression levels of both genes. No significant differ-
ences between the control and the WD groups were either found regarding expression levels of ATGL protein, 
but animals of the HESP + CAP group displayed lower levels than the control and HESP groups (P < 0.05, LSD 
post-hoc analysis).
The expression of the fatty acid oxidation related gene Cpt1b showed a pattern of expression similar to that 
described for the Lpl in the CAP and HESP + CAP groups, and to a lesser extent the HESP group, showing lower 
expression levels than the control and WD groups (P < 0.05, LSD post-hoc analysis).
Figure 4. mRNA expression levels and protein levels of Trpv1 and Ucp2 in liver of control (C), western diet 
(WD), hesperidin (HESP), capsaicin (CAP), and hesperidin and capsaicin (HESP + CAP) rats at the end of 
treatment. mRNA levels were measured by real-time PCR. Specific protein levels were measured by western 
blot. Representative bands for TRPV1 and UCP2 (deriving for each protein from the same gel), together with 
β-actin are shown. mRNA and protein levels were expressed as a percentage of the control group. Data are 
mean ± SEM (n = 7–8). Statistical analysis between groups was performed by one-way ANOVA, followed by 
LSD post-hoc analysis (P < 0.05), a ≠ b ≠ c.
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As far as glucose uptake and metabolism are concerned, the CAP and HESP + CAP groups also showed lower 
expression levels of the Slc2a4 and Hk2 genes when compared to the control, WD and HESP groups. In turn, the 
HESP group showed lower expression levels of Slc2a4 than the controls and of Hk2 than the WD group (P < 0.05, 
LSD post-hoc analysis). No significant differences were found between the control and the WD groups concerning 
the expression levels of both genes.
Regarding insulin signalling, the HESP, CAP and HESP + CAP groups showed reduced expression levels of 
the Insr gene with respect to the WD group (P < 0.05, LSD post-hoc analysis). The decrease was more marked 
in the CAP and HESP + CAP groups, which also showed lower expression levels than those of the HESP and 
the control groups. A similar pattern was observed regarding INSRβ protein levels. The CAP and HESP + CAP 
groups expressed lower INSRβ protein levels than animals of the WD group (P < 0.05, LSD post-hoc analysis), but 
no significant differences were found between the WD and CAP groups.
Figure 5. mRNA expression levels and protein levels of genes related to energy metabolism (lipogenesis, 
fatty acid uptake, lipolysis, fatty acid oxidation, glucose uptake and metabolism, and insulin signalling) in 
retroperitoneal white adipose tissue of control (C), western diet (WD), hesperidin (HESP), capsaicin (CAP), 
and hesperidin and capsaicin (HESP + CAP) rats at the end of treatment. mRNA levels were measured by 
real-time PCR. Specific protein levels were measured by western blot. Representative bands for LPL, ATGL 
and INSRβ (deriving for each protein from the same gel), together with β-actin are shown. mRNA and protein 
levels were expressed as a percentage of the control group. Data are mean ± SEM (n = 7–8). Statistical analysis 
between groups was performed by one-way ANOVA, followed by LSD post-hoc analysis (P < 0.05), a ≠ b ≠ c.
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In vitro assessment of the effects of hesperidin, capsaicin, and the combination of both com-
pounds on Trpv1 and Ucp2 expression. Direct effects of hesperidin and capsaicin, individually and 
in combination, on mRNA of Trpv1 and Ucp2 were assessed in vitro in the human hepatoma-derived cell line 
HepG2 (Fig. 6). Results showed that capsaicin (1 μmol/L) treatment, but not the combination of hesperidin (10 
μmol/L) + capsaicin (1 μmol/L), resulted in higher Trpv1 mRNA levels compared with the vehicle (P < 0.05, 
Student’s t test). No effects were found with the lower doses assayed (5 μmol/L hesperidin, 0.5 μmol/L capsaicin). 
Regarding Ucp2, both hesperidin (10 μmol/L) and capsaicin (1 μmol/L), separately, resulted in higher expression 
levels of Ucp2 compared with the vehicle (P < 0.05, Student’s t test); however, no effect was found with the com-
bination of both compounds. No significant effects were found with the lower doses studied of both compounds.
Discussion
The prevalence of obesity and its related metabolic complications has increased in the last decades at an epidemic 
rate, becoming a serious global health problem1. Feeding behaviour, and particularly the intake of a high-fat, 
high-sucrose diet, the so called western diet, may be considered as one of the main determinants2. Besides nutri-
tional advises, the development of food-related strategies to prevent or attenuate metabolic syndrome related 
consequences is of great interest.
Studies performed in last decades have pointed out the bioactive effects of the flavonoid hesperidin 
against obesity-related alterations, mainly because to its TG-lowering, anti-inflammatory, antioxidant, and 
insulin-sensitizing effects5–9,26. In turn, capsaicin has a demonstrated anti-obesity effect. It has been shown to 
reduce body weight gain, hepatic lipid accumulation and insulin resistance induced by high-fat diet feeding in 
animals13,14. Thus, both hesperidin and capsaicin might be promising bioactives for prevention or treatment of 
metabolic syndrome components, with potential complementary action. However, the potential benefits of the 
combination of both compounds preventing or ameliorating diet-induced alterations had not been explored yet. 
Here, we assessed the effects of hesperidin and capsaicin, alone and in combination, to prevent metabolic altera-
tions related to the metabolic syndrome in rats exposed to a western diet.
As expected, the consumption of a western diet for 8 weeks in adult rats resulted in a higher body weight and 
body fat gain, and, thereby, the animals exhibited at the end of treatment greater fat content than animals fed 
standard diet. Moreover, western diet-fed animals displayed greater leptin levels and higher TG and NEFA levels 
in the fed state than the controls. Interestingly, capsaicin treatment (4 mg/kg/day) during 2 months in western 
diet-fed animals effectively reduced body fat gain, as well as fed-state levels of leptin and NEFA. In turn, hesperi-
din treatment (100 mg/kg/day) attenuated body fat increase, as well as the increase in circulating leptin levels 
associated to western diet feeding, but the effects were lower than those observed by capsaicin and did not reach 
statistical significance. Other authors have also found no significant effects of hesperidin on body weight in obese 
mice under low-fat diet, but significant effects were observed when hesperidin was combined with caffeine27. 
Notably, the combination of hesperidin and capsaicin did show lower effects on body fat gain than those induced 
by capsaicin alone; in fact, body fat percentage of these animals at the end of the treatment was similar to that of 
animals treated with hesperidin, and not different from that of western diet-fed animals.
The anti-obesity action of capsaicin (and non-pungent related compounds) has been previously described in 
both animal and human studies. Evidence suggests that capsaicin decreases body weight by increasing energy 
expenditure28–32, stimulating adipose tissue lipid mobilization and fat oxidation30,31,33,34, and reducing energy 
intake29,32,35,36; however, its concrete mechanism is not clear.
In the present study we show that animals receiving either hesperidin or capsaicin, separately, or the combi-
nation, along with a western diet, showed a trend to eat fewer calories than western diet-fed animals (decreases 
of 5.4%, 7.4% and 7.1%, respectively), reaching values not different from that of the controls. However, no addi-
tive effects were found with the combination of both compounds. Thus, the lower intake may contribute to the 
Figure 6. mRNA levels of Trpv1 and Ucp2 in HepG2 cells treated with hesperidin (HESP) (5 μmol/L and  
10 μmol/L), capsaicin (CAP) (0.5 μmol/L and 1 μmol/L), the combination of both HESP + CAP, or the vehicle 
for 24 hours. mRNA levels were measured by real-time PCR and expressed as a percentage of the vehicle group. 
Data are mean ± SEM (n = 7–12). Non significant differences were found between groups by one-way ANOVA, 
followed by LSD post-hoc analysis (P < 0.05). #Different from vehicle (P < 0.05, Student’s t test).
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lower body fat gain of animals, more marked for the animals that received capsaicin. Nevertheless, in spite of the 
described effects of capsaicin increasing energy expenditure, we did not observe any significant enhancement in 
energy expenditure induced by capsaicin, or by hesperidin, at 6 weeks of treatment. The lack of significant effects 
might be tentatively explained by a reduced sympathetic responsiveness to capsaicin treatment in western diet 
fed-rats, as described in obese subjects37, which may impair diet-induced thermogenesis; however, the thermo-
genic effects of capsaicin in white and brown adipose tissues have not been directly explored here.
The effects of capsaicin in preventing fat accumulation may be explained, at least in part, by the effects on lipid 
metabolism in adipose tissue, particularly by its lipogenesis inhibitory effect38. In fact, animals treated with capsaicin 
displayed in rWAT decreased expression levels of lipogenesis-related genes (Pparg and Srebf1), along with decreased 
expression levels of genes related with fatty acid uptake (Lpl, Cd36) and oxidation (Cpt1b), lipolysis (Pnpla2, Lipe), 
and glucose uptake and metabolism (Slc2a4, Hk2). These effects may be tentatively related with a decreased insulin 
action in the adipose tissue, as deduced from the trend to lower insulin levels found in animals in the capsaicin 
group, together with the decreased mRNA levels of the Insr gene and of INSRβ protein levels with respect to animals 
in the WD group. Expression levels of some of the above-mentioned genes (Pparg, Lpl, Pnpla2, Cpt1b, Hk2, and 
Insr) were also diminished in animals treated with hesperidin, with respect to western diet-fed animals, but the 
effects were generally less marked than those observed with capsaicin, in accordance with the more modest effect of 
hesperidin on body fat gain. The combination of capsaicin and hesperidin also elicited no additional effects to those 
observed with capsaicin alone, with the exception of ATGL, whose protein levels were only significantly lower in the 
group treated with the combination of compounds with respect to the control group.
According to the improvement of lipid metabolism in adipose tissue, capsaicin treatment also showed 
interesting effects in preventing diet-induced insulin resistance. Capsaicin treatment prevented the increase in 
HOMA-IR in western diet-fed rats, but notably, the effects were reduced when capsaicin was combined with hes-
peridin. The capacity of capsaicin in ameliorating insulin resistance has been previously described in rodents13. 
Several studies in humans have also revealed that capsaicin has a modest effect in type 2 diabetes39. Unlike capsa-
icin, no significant effects were observed for hesperidin on insulin resistance in western diet-fed rats.
Treatment with either hesperidin or capsaicin alone, but not with the combination of both bioactives, atten-
uated the increase of circulating TG levels in the fed-state occurring in western diet-fed rats. In addition, both 
compounds separately, and to a lesser extent the combination, attenuated hepatic lipid increase due to western 
diet feeding. Moreover, histological analysis unveiled that both hesperidin and capsaicin, when administered 
alone, conferred protective effect on the development of non-alcoholic fatty liver disease (NAFLD) and prevented 
the features of non-alcoholic steatohepatitis (NASH), such as hepatocyte ballooning, necrotic hepatocytes and 
infiltrated lymphocytes, found in western diet-fed animals. However, some signs of NASH were found in animals 
treated with the combination of both bioactives. Despite this, no significant differences were found between 
groups in the plasma levels of the liver damage markers AST and ALT. A sex-dependent effect has been described 
regarding the risk of developing NAFLD and NASH in animal and human studies, since males are at an increased 
risk compared with females40. Therefore, one of the limitations of the present study is that this has only been per-
formed in male rats. This must be considered when extrapolating the results to humans.
Hesperidin has been previously described to reduce serum TG in animal models41–43 and hypertriglyceridemic 
subjects7. The mechanisms involved in the TG-lowering effects of hesperidin have been reported to be the reduction 
of hepatic TG content through inhibition of lipogenesis and induction of fatty acid oxidation43, and the downregula-
tion of synthesis and secretion of very-low-density lipoproteins (VLDL)44. According to this notion, we observed here 
that hesperidin-treated animals displayed decreased expression levels of three key lipogenesis-related genes, Srebf1, 
Fasn and Scd1, as well as normalisation of Pklr gene expression to control levels. In addition, these animals exhibited 
decreased hepatic expression levels of the Insr and Lepr genes, compared to levels of expression in western diet-fed 
rats, suggesting a decreased lipogenic action of insulin, along with decreased fatty oxidation activity. Although there is 
no clear consensus in the literature on the effects of leptin in liver45, it has been proposed that leptin may have insulin 
sensitizing effects, controlling the extent of insulin action on this tissue46. Notably, disruption of hepatic leptin signalling 
has been shown to protect mice from diet-related glucose intolerance46. Therefore, it is suggested that the decreased 
hepatic lipogenesis in hesperidin-treated animals, associated to a decreased insulin action on this tissue, may be one of 
the mechanisms whereby this bioactive protects against diet-induced hepatic pathologies.
In turn, capsaicin treatment elicited little effects on the expression of hepatic lipogenesis-related genes com-
pared to changes observed with hesperidin. It has been reported that capsaicin regulates hepatic lipid metab-
olism and prevent lipid deposition in liver through TRPV1 activation19. Capsaicin action on TRPV1 involves 
up-regulation of UCP2, a mitochondrial membrane transporter that can provide fatty acid translocation, pre-
venting its accumulation in the mitochondrial matrix19. Here, the presence of higher mRNA levels of Ucp2 and of 
the encoded protein UCP2 in capsaicin-treated animals compared to the other groups is in accordance with the 
involvement of UCP2 in the protective effects of capsaicin on lipid deposition in liver, providing protective effects 
from hepatocellular lipotoxicity47. Therefore, both capsaicin and hesperidin, separately, are able to overcome the 
effects of western diet on hepatic lipid metabolism, and hence ameliorate hepatic steatosis and prevent NASH 
associated with western diet consumption. Unexpectedly, the effects were blunted or even negligible when ani-
mals were treated with both compounds simultaneously. Mechanisms underlying this interaction are unknown, 
but the comparison of gene expression patterns in liver has given some clues. On the one hand, capsaicin treat-
ment blocked the decrease in the hepatic expression of Lepr induced by hesperidin, which may be tentatively 
associated with an increase in insulin-induced lipogenesis activity in this tissue. In fact, the combination of both 
compounds up-regulated the expression of the lipogenic gene Gadph, reaching levels higher than those of animals 
treated with hesperidin alone. On the other hand, hesperidin seems to override the effects of capsaicin through its 
TRPV1 receptor. The induction of Trpv1 expression by capsaicin was attenuated with the simultaneous treatment 
with hesperidin, suggesting that the responsiveness to the capsaicin action was blunted in animals treated with 
the combination of bioactives. Accordingly, animals treated with the combination of bioactives did not show the 
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increase in Ucp2 mRNA levels or in UCP2 protein levels characteristic of capsaicin treated animals. Thus, it is 
suggested that both bioactives may mutually impair their ways of action on the improvement of liver health in 
western diet-fed animals. This hypothesis is supported by the results of an in vitro assay in the human liver HepG2 
cell line, showing that the combination of hesperidin and capsaicin, blunts the effects of capsaicin on the increase 
of Trpv1 and Ucp2 expression levels.
Finally, regarding other components of the metabolic syndrome, results of the present study also bring evi-
dence supporting the hypotensive effects of hesperidin and, to a lesser extent, of capsaicin. In fact, systolic and 
diastolic blood pressure was decreased in hesperidin treated animals, compared to untreated western diet-fed 
rats, reaching levels lower than the controls. Animals treated with capsaicin or the combination of hesperidin and 
capsaicin also exhibited lower diastolic blood pressure than western diet-fed animals, and similar to control ani-
mals. This suggests interesting anti-hypertension effects of hesperidin, beyond their potential fat-lowering effects. 
The hypotensive effect of hesperidin has been previously described both at short- and long-term treatments in 
models of hypertensive rats48,49, and this has been related to the capacity to improve endothelium-dependent 
vasorelaxation by increasing the availability of nitric oxide50,51.
In summary, the results of the present study show that capsaicin and hesperidin, separately, exhibit different 
effects on fat accumulation and metabolic syndrome-related disorders in rats fed on western diet. More precisely, 
capsaicin induces protective phenotype against obesity, decreasing body fat gain and preventing insulin resistance 
under western diet feeding, whereas hesperidin has little effects on body fat gain and no apparent effects on insu-
lin resistance. No additive effects, or even blunted with respect to those observed with capsaicin, were observed 
with the combination of both bioactives. However, capsaicin and hesperidin alone, improve blood lipid profile, 
diminish hepatic lipid accumulation, and prevent NASH in western diet-fed rats, although the effects are miti-
gated or even annulled with the combination of both compounds. In turn, hesperidin alone, and to a lesser extent 
capsaicin or the combination of hesperidin plus capsaicin, display hypotensive effects in western diet-fed rats. 
Therefore, these results give additional evidence supporting that intervention with either capsaicin or hesperidin 
alone may be promising in populations at high risk of metabolic syndrome-related alterations, particularly fatty 
liver disease. However, negative results found with the combination of both compounds deserve to be taken into 
account when considering potential mixtures of bioactives as strategies for obesity prevention.
Methods
Animals and experimental design. The animal protocol followed was reviewed and approved by the 
Bioethical Committee of the University of the Balearic Islands (Resolution Number 7619, October, 2015) and 
guidelines for the use and care of laboratory animals of the University were followed.
The study was performed in 39 three-month-old male Wistar rats randomly divided into 5 groups: Control 
(n = 7), animals fed with a standard chow diet (3.3 kcal/g, with 19% kcal from protein, 73% from carbohydrate, 
and 8% from fat) (Pan-lab, Barcelona, Spain); WD (n = 8), animals fed with a high-fat, high-sucrose diet (western 
diet, 4.7 kcal/g, with 17% kcal from protein, 43% from carbohydrate, and 41% from fat) (Research Diets, Inn, New 
Brunswick, NJ, USA); HESP (n = 8), animals fed with a western diet and treated with hesperidin (100 mg/kg/day); 
CAP (n = 8), animals fed a western diet and treated with capsaicin (4 mg/kg/day); and HESP + CAP (n = 8), ani-
mals fed with a western diet and treated with the combination of hesperidin (100 mg/kg/day) and capsaicin (4 mg/
kg/day). Hesperidin and capsaicin were purchased from Aldrich Co. LLC. (St. Louis, MO). They were prepared in 
0.9% saline and administered orally, by gavage, once a day after the beginning of the light cycle (8:00 h). Control and 
WD groups received the same volume of saline (1 mL/kg). The animals were kept with this treatment for 8 weeks, 
until they were 5 months old. All rats were individually housed under controlled temperature (22 °C) and a 12 hours 
light-dark cycle, and had unlimited access to tap water and standard diet or western diet, depending on the group.
Body weight and body composition (by EchoMRI-700TM, Echo Medical Systems, LLC., TX, USA) were 
measured at baseline and at the end of the treatment (week 8). Blood samples were obtained on week 7 after 
12 hours fasting from saphenous vein and at sacrifice under feeding conditions (truncal blood). Blood samples 
were collected in heparinized containers, then centrifuged at 1000 g for 10 min to obtain the plasma, and stored 
at 20 °C until analysis. After 8 weeks of treatment, animals were sacrificed by decapitation under fed condition. 
Retroperitoneal white adipose tissue (rWAT) and the liver were rapidly removed, weighted, frozen in liquid nitro-
gen, and stored at −80 °C until subsequent studies.
Indirect calorimetry and locomotive activity measurements. Animals were monitored 
for 24 hours to assess energy expenditure by indirect calorimetry and locomotive activity by using the 
LabMaster-CalSys-Calorimetry System (TSE Systems, Bad Homburg, Germany) after 6 weeks of treatment. In 
order to reduce potential stress, animals were individually housed and acclimated to the respiratory cages for 
24 hours before the measurement began. Data on gas exchanges (VO2; ml kg −1 h−1 and VCO2; ml kg −1 h−1) were 
measured via an open circuit indirect calorimetry system for 24 hours Rates of oxygen consumption and carbon 
dioxide production were monitored for 5 min every 45 min for each animal or reference cage (our system can 
handle 8 animal cages and 1 reference cage, simultaneously). Mean energy expenditure (kcal/h) and respiratory 
exchange ratio (RER) values were calculated over 24 hours. Locomotive activity (counts/h) was measured contin-
uously by an infrared beam system integrated in the LabMaster System for 24 hours.
Blood pressure measurement. Systolic and diastolic blood pressure was measured after 5 weeks of treat-
ment. This was determined without anaesthesia using non-invasive blood pressure methodology. It consists of 
using a tail-cuff sphygmomanometer with a photoelectric sensor (Niprem 546, Cibertec S.A., Spain) placed on 
the animal’s tail to occlude the blood flow. Niprem software V1.8 was used. All measurements were carried out 
between 1600 and 1900 h. For each animal, systolic and diastolic blood pressure values were calculated as the 
mean of five measurements.
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Measurement of circulating parameters. Fresh blood glucose concentration was measured with an 
Accu-Chek Glucometer (Roche Diagnostics, Barcelona, Spain). Commercial rat ELISA kits were used for the quanti-
fication of circulating plasma levels of insulin (inter- and intra-assay coefficient of variation were in the range between 
2.8–5.1% and 3.2–10%, respectively, Mercodia AB, Uppsala, Sweden), and leptin (inter- and intra-assay coefficient 
of variation were in the range between 3.3–4.3% and 4.7–7.6%, respectively, R&D Systems, Minneapolis, MN, USA). 
Commercial enzymatic kits were used for determination of plasma levels of TG (Triglyceride (INT) 20, (Sigma-Aldrich 
Co., LLC, Madrid, Spain), non-esterified fatty acids (NEFA) (Wako Chemicals GmbH, Neuss, Germany), and aspartate 
transaminase (AST) and alanine transaminase (ALT) (QCA, Química Clínica Aplicada S.A., Tarragona, Spain), each 
one according to the manufacturer’s instructions. The homeostatic model assessment for insulin resistance (HOMA-IR) 
was used to assess insulin resistance according to the formula described by Matthews and collaborators52.
Quantification of hepatic lipid content. Total lipids were extracted from about 600 mg of hepatic tissue 
and quantified by the method of Folch et al.53.
Histological analysis. Liver samples of 5 animals per group were used for histological analysis. Liver tissue 
samples were fixed by immersion in 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) overnight 
at 4 °C. Following, they were washed in phosphate buffer, dehydrated in a graded series of ethanol, cleared in 
xylene and embedded in paraffin blocks. Five-micrometer-thick sections of tissues were cut with a microtome 
and mounted on slides.
Liver sections were classified into four grades depending on fat accumulation following Burnt et al. classifi-
cation21: grade 0 was assigned when there was no fat accumulation; grade 1 when fat vacuoles were observed in 
less than 33% of hepatocytes; grade 2 when 33–66% of hepatocytes contained fat vacuoles; and grade 3 when they 
were found in more than 66% of hepatocytes.
RNA Extraction. Total RNA was extracted from the liver by Tripure Reagent (Roche Diagnostic Gmbh, 
Mannheim, Germany) and from retroperitoneal white adipose tissue (rWAT) by an E.Z.N.A. RNA purification 
system (Omega Biotek, Inc., Norcross, GA) each one according to the manufacturer’s instructions. Isolated RNA 
was quantified using NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies Wilmington, DE, USA). 
Its integrity was confirmed using agarose gel electrophoresis.
Real-time quantitative PCR analysis. Real-time polymerase chain reaction was used to measure mRNA 
expression levels of selected genes in the liver and rWAT. Precisely, in liver: sterol regulatory element binding 
transcription factor 1 (Srebf1), fatty acid synthase (Fasn), sterol coenzyme A desaturase (Scd1), glyceraldehyde 
3-phosphate dehydrogenase (Gadph), carnitine palmitoyltransferase 1a, liver (Cpt1a), peroxisome proliferator 
activated receptor alpha (Ppara), fibroblast growth factor 21 (Fgf21), Glucokinase (Gck), pyruvate kinase (Pklr), 
insulin receptor (Insr), insulin receptor substrate 1 (Irs1), leptin receptor (Lepr), transient receptor potential cat-
ion channel, subfamily V, member 1 (Trpv1), and uncoupling protein 2 (Ucp2). In WAT: peroxisome proliferator 
activated receptor gamma (Pparg), Srebf1, Fasn, glycerol-3-phosphate acyltransferase (Gpat), lipoprotein lipase 
(Lpl), CD36 molecule (Cd36), patatin-like phospholipase domain containing 2 (Pnpla2), hormone-sensitive 
lipase (Lipe), carnitine palmitoyltransferase 1b, muscle isoform (Cpt1b), glucose transporter 4 (Slc2a4), hexoki-
nase II (HK2), and Insr. Guanosine Diphosphate Dissociation Inhibitor (Gdi) was used as a reference gene. All 
primers were obtained from Sigma Genosys (Sigma Aldrich Co., LLC, Madrid, Spain).
Total RNA (0.25 μg, in a final volume of 5 μL) was denatured at 65 °C for 10 min and then reverse transcribed 
to cDNA using MuLV reverse transcriptase (Applied Biosystems, Madrid, Spain) at 20 °C for 15 min and 42 °C for 
30 min with a final step of 5 min at 95 °C in an Applied Biosystems 2720 Thermal Cycler (Applied Biosystems). 
Each polymerase chain reaction (PCR) was performed from diluted (1/20) cDNA template, forward and reverse 
primers (1 μmol/L each), and Power SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA). 
Real-time PCR was performed using the Applied Biosystems StepOnePlus real-time PCR system with the follow-
ing profile: 10 min at 95 °C, followed by a total of 40 two-temperature cycles (15 s at 95 °C and 1 min at 60 °C). To 
verify the purity of the products, a melting curve was produced after each run according to the manufacturer’s 
instructions. The threshold cycle (Ct) was calculated by the instrument’s software (StepOne Software v2.2.2), and 
the relative expression of each mRNA was calculated as a percentage of male control rats using de 2−ΔΔCt method.
Western blot analysis. Protein levels of adipose triglyceride lipase (ATGL) (Cayman, Michigan, USA), 
CPT1 (Santa Cruz Biotechnology, Inc., Heidelberg, Germany), LPL (Santa Cruz Biotechnology, Inc.), INSRβ (Cell 
Signaling Technology, Leiden, The Netherlands), TRPV1 (Thermo Fisher Scientific, Madrid, Spain) and UCP2 
(Abcam, Cambridge, UK) in liver or rWAT were determined by western blot. Tissues were homogenized at 4 °C 
in 1:10 (w:v) for liver and 1:2 (w:v) for rWAT of phosphate buffer saline, and then processed for western blot as 
previously described54 with some modifications. For analysis, 50 or 60 µg total protein was fractionated by a 10% 
or a 4–15% SDS-PAGE (CriterionTMTGXTM, Bio-Rad Laboratories, Madrid, Spain) and then electrotransferred 
onto nitrocellulose membrane (Bio-Rad Laboratories). After blocking, membranes were incubated with the cor-
responding primary antibody, and then with the infrared-dyed secondary anti-IgG antibody (LI-COR Biociences, 
Nebraska, USA). For IR detection, membranes were scanned in Odyssey Infrared Imaging System (LI-COR 
Biociences) and bands were quantified using Odyssey Software V.3.0 (LI-COR Biosciences). Housekeeping pro-
tein used was β-Actin (Cell Signaling Technology, Leiden, The Netherlands).
Cell culture and treatments. HepG2 cells, a human hepatoma-derived cell line, were obtained from ATCC 
(American Type Culture Collection; LGC Deselaers SL, Barcelona, Spain). They were grown in eagles minimum 
essential medium (EMEM) (ATCC) supplemented with 10% (v/v) fetal bovine serum (Gibco, Thermofisher 
Scientific, Madrid, Spain) and antibiotics (50 IU penicillin/mL and 50 mg streptomycin/mL) at 37 °C, in a humidified 
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atmosphere with 5% CO2. The cells (approximately 3 × 103 cells per cm2) were plated in 24-well cell culture plates 
and cultured for 10 days, with medium changes every 3–4 days. When the culture cells reached approximately 90% 
confluence, they were treated for 24 h with 0.5 and 1 μmol/L of capsaicin (Sigma Aldrich, St. Louis, MO, USA), 5 
and 10 μmol/L of hesperidin (Sigma Aldrich, St. Louis, MO, USA), and the mixture of both compounds (0.5 μmol/L 
capsaicin + 5 μmol/L hesperidin, and 1 μmol/L capsaicin + 10 μmol/L hesperidin). The concentrations of capsaicin 
assayed were selected from the literature. 1 μmol/L capsaicin has been shown to stimulate Trpv1 expression in por-
cine iliac artery endothelial cells55. Regarding hesperidin, the concentrations were selected to keep the proportion 
with respect to capsaicin tested in the in vivo study. Capsaicin was prepared in ethanol and hesperidin in water. All 
wells received the same amount of water and ethanol. After treatment, total RNA was extracted with E.Z.N.A. RNA 
purification system, and mRNA levels of Trpv1 and Ucp2 were measured as previously described56. 
Statistical Analysis. All data are expressed as the mean ± Standard Error of the Mean (SEM). Data were 
checked for normality using Shapiro-Wilks normality test. For multi-group comparisons Levene’s test was per-
formed to assess whether the variance is equal between groups; if the variance was heterogeneous, data were 
log-transformed before analysis. Differences among groups were assessed by one-way ANOVA followed by 
least significances difference (LSD) post-hoc comparison. The effect of fasting versus ad libitum feeding in blood 
parameters was assessed with a paired t test. Student’s t test was performed to assess differences in gene expression 
in in vitro studies to compare the different treatments versus the vehicle. The analyses were performed with IBM 
SPSSP Statistics 21. Threshold of significance was defined at P < 0.05.
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